Flaviviruses such as Zika virus, dengue virus, West Nile virus, yellow fever virus, and Japanese encephalitis virus cause widespread illness and death throughout the world. Typically, flaviviruses get transmitted through the bite of infected mosquitoes and ticks.
Inventor First Name:
Brent
Gwong-Jen
Inventor Last Name:
Davis
Chang
E Number Only:
E-203-2018
Inv Is lead:
Pat Filing Date:
2020-05-08
Provider Technology ID:
3433
Patent Application:
63/021,852
LPM Zip:
20892-9804
LPM Organization:
NIH Office of Technology Transfer
LPM Phone:
301-443-8518
LPM State:
MD
- Antibody
- Gene-based
- Vaccine
Updated On:
Friday, February 19, 2021
Related Patent Publish Date:
Friday, January 26, 2018
Related Invention:
E-030-2017-0
Related Patent Application:
62/622,521
LPM Last Name:
Mitzelfelt
LPM FIrst Name:
Jeremiah
Development Stage:
Date Published:
Friday, February 19, 2021
DTDT Classification:
Infectious Diseases (viral)
Zoonotic/Veterinary
Diagnostic
Monitoring (Public Health/Counterfeit Detection/Biological)
Quality Control/Quality Assurance
Research Tool
Other (this will include others such as manufacturing, consumer products and vet
Antibody
Gene-based
In vitro data available
In vivo data available (animal)
Vaccine
Vaccine
DTDT Description:
Infectious Diseases (viral)
Zoonotic/Veterinary
Diagnostic
Monitoring (Public Health/Counterfeit Detection/Biological)
Quality Control/Quality Assurance
Research Tool
Other (this will include others such as manufacturing, consumer products and vet
Antibody
Gene-based
In vitro data available
In vivo data available (animal)
Vaccine
Vaccine
Collaboration Sought:
Yes
Collaboration Opportunity:
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Stable Human Cell Lines Expressing Flavivirus Virus-Like Particles (VLPs) for Vaccine, Biologics, and Diagnostic Development. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.
Advantages:
- Suitable for use as human and animal vaccines and diagnostic antigens
- VLP strategy has proven effectiveness in CDC's West Nile virus (WNV) and dengue vaccine development
- Some of these antigens are being utilized in commercially available FDA-approved diagnostic test kits
- Stable over time (e.g., some clones for a year) without sign of gene expression deterioration
- Produced from FDA-approved cell lines
- Selected without antibiotics and propagated in a serum-free and animal protein-free culture media
- Partners can directly incorporate the cell lines into a manufacturing pipeline for vaccines, biologics, or diagnostics
Application:
Monitoring
(Public Health/Counterfeit Detection/Biological)
Applications:
- For use in human and animal vaccine and biologics development against flaviviruses such as dengue virus, yellow fever virus, Zika virus, Japanese encephalitis, West Nile virus, Japanese encephalitis virus, St. Louis encephalitis virus, Powassan virus, and others
- Improved serological diagnostics for flaviviruses in humans and animals and adaptable to kit format
- Public health monitoring and surveillance for flaviviruses
- Quality assurance and quality control for vaccine development
- Research and development
NIH Ref. No.:
E-203-2018-0
IC:
CDC
LPM Address:
BG 5601FL RM 2G29 MSC 9804
5601 FISHERS LN
LPM City:
Bethesda
LPM Email:
jeremiah.mitzelfelt@nih.gov
Inventor IC:
CDC
CDC
Institute or Center:
Lead Inventor:
